Literature DB >> 32628416

Considerations for the otolaryngologist in the era of COVID-19: a review of the literature.

Lauren E Miller1, David A Shaye, Linda N Lee.   

Abstract

PURPOSE OF REVIEW: The SARS-CoV-2 coronavirus pandemic, referred to as COVID-19, has spread throughout the globe since its first case in China in December 2019, leaving a significant number of people infected and clinically ill. The purpose of this review is to provide the current known clinical characteristics of and management for COVID-19 as it relates to otolaryngology. RECENT
FINDINGS: COVID-19 is a highly transmissible respiratory disease with common presenting symptoms of fever, cough, and fatigue. In the absence of available vaccines or antiviral therapies, symptomatic and respiratory support is the current standard of therapy. Measures to prevent further transmission have been enacted globally including social distancing and cancellation of public events. Given elevated viral load in the upper aerodigestive tract, extra precautions in patients with otolaryngology needs have been recommended for protection of both healthcare workers and patients.
SUMMARY: Otolaryngologists face unique risk from COVID-19. Maintaining appropriate preventive health measures and remaining updated on institutional clinical guidelines is paramount for both caretaker safety and patient care.

Entities:  

Mesh:

Year:  2020        PMID: 32628416     DOI: 10.1097/MOO.0000000000000632

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  2 in total

1.  Pandemics and facial plastics and reconstructive surgery.

Authors:  Lisa Morris
Journal:  Oper Tech Otolayngol Head Neck Surg       Date:  2022-04-27

2.  The influence of SARS-CoV-2 vaccination on post-operative outcomes in microsurgery patients.

Authors:  Susan M Taghioff; Benjamin R Slavin; Manish Narasimman; Georges Samaha; Mario Samaha; Tripp Holton; Devinder Singh
Journal:  Microsurgery       Date:  2022-07-15       Impact factor: 2.080

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.